×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Theseus Pharmaceuticals Inc. (THRX) NASDAQ

$4.06 - (-)

Market Cap: -

As of 02/13/24 12:00 AM EST. Market closed.

(THRX)

Theseus Pharmaceuticals Inc. (THRX)
NASDAQ

$4.06
- (-)

Market Cap: -

As of 02/13/24 12:00 AM EST. Market closed.

Add to Portfolio

theseus pharmaceuticals is passionately committed to outsmarting cancer resistance. cancer is constantly mutating, allowing it to evade initially effective oncology treatments. theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. led by a team of pioneers in the discovery and ... read more

theseus pharmaceuticals is passionately committed to outsmarting cancer resistance. cancer is constantly mutating, allowing it to evade initially effective oncology treatments. theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (tkis), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Address
.
PRICE CHART FOR THESEUS PHARMACEUTICALS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$4.06
Days Range
$4.06 - $4.07
52 week range
- - -
Volume
3,123,140
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
44,230,135
Open
-
Previous Close
$4.06
Days Range
$4.06 - $4.07
52 week range
- - -
Volume
3,123,140
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
44,230,135
FINANCIAL STATEMENTS FOR THESEUS PHARMACEUTICALS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR THESEUS PHARMACEUTICALS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Shakespeare WilliamSee RemarksNov 06, 2023 Option Exercise$0.32251,08480,347639,408Nov 07, 2023, 04:03 PM
GORDON CARL LDirectorJul 17, 2023 Buy$3.05479,9321,463,79317,063,000Jul 19, 2023, 04:17 PM
ORBIMED ADVISORS LLCDirectorJul 17, 2023 Buy$3.05479,9321,463,79317,063,000Jul 19, 2023, 04:15 PM
Foresite Capital Management V, LLC10% OwnerJul 17, 2023 Buy$2.97700,0002,079,0004,108,796Jul 19, 2023, 02:54 PM
Foresite Capital Management V, LLC10% OwnerDec 29, 2022 Buy$5.00500,0002,500,0003,585,346Jan 03, 2023, 04:24 PM
HAYDEN DONALD J JRDirectorDec 29, 2022 Buy$5.00100500100Jan 03, 2023, 07:05 AM
HAYDEN DONALD J JRDirectorDec 30, 2022 Buy$5.009,90049,48910,000Jan 03, 2023, 07:05 AM
Dahms Bradford D.Chief Financial OfficerNov 30, 2022 Buy$6.661,5029,9996,142Dec 01, 2022, 04:35 PM
CLACKSON TIMOTHY PPresident and CEONov 11, 2022 Buy$6.802,50016,995351,030Nov 14, 2022, 04:12 PM
GORDON CARL LDirectorNov 07, 2022 Buy$5.21192,0001,000,32016,734,518Nov 09, 2022, 04:29 PM
ORBIMED ADVISORS LLCDirectorNov 07, 2022 Buy$5.21192,0001,000,32016,734,518Nov 09, 2022, 04:25 PM
GORDON CARL LDirectorJan 20, 2022 Buy$9.9535,000348,25016,430,756Jan 21, 2022, 07:22 PM
GORDON CARL LDirectorJan 19, 2022 Buy$9.9711,521114,86416,395,756Jan 21, 2022, 07:22 PM
GORDON CARL LDirectorJan 21, 2022 Buy$9.97111,8961,115,60316,542,652Jan 21, 2022, 07:22 PM
ORBIMED ADVISORS LLCDirectorJan 21, 2022 Buy$9.97111,8961,115,60316,542,652Jan 21, 2022, 07:18 PM
ORBIMED ADVISORS LLCDirectorJan 20, 2022 Buy$9.9535,000348,25016,430,756Jan 21, 2022, 07:18 PM
ORBIMED ADVISORS LLCDirectorJan 19, 2022 Buy$9.9711,521114,86416,395,756Jan 21, 2022, 07:18 PM
GORDON CARL LDirectorJan 11, 2022 Buy$10.518,50089,31916,348,018Jan 13, 2022, 07:27 PM
GORDON CARL LDirectorJan 13, 2022 Buy$9.4317,320163,32816,384,235Jan 13, 2022, 07:27 PM
GORDON CARL LDirectorJan 12, 2022 Buy$10.0618,897190,10416,366,915Jan 13, 2022, 07:27 PM
ORBIMED ADVISORS LLCDirectorJan 13, 2022 Buy$9.4317,320163,32816,384,235Jan 13, 2022, 07:18 PM
ORBIMED ADVISORS LLCDirectorJan 12, 2022 Buy$10.0618,897190,10416,366,915Jan 13, 2022, 07:18 PM
ORBIMED ADVISORS LLCDirectorJan 11, 2022 Buy$10.518,50089,31916,348,018Jan 13, 2022, 07:18 PM
CLACKSON TIMOTHY PPresident and CEODec 21, 2021 Buy$9.762,60025,381348,530Dec 22, 2021, 06:26 PM
Dahms Bradford D.Chief Financial OfficerDec 21, 2021 Buy$10.151,97020,0001,970Dec 22, 2021, 06:21 PM
GORDON CARL LDirectorOct 12, 2021 Buy$16.0062,5001,000,000499,150Oct 14, 2021, 05:00 PM
GORDON CARL LDirectorOct 12, 2021 Buy$16.00562,5009,000,00016,339,518Oct 14, 2021, 05:00 PM
Shakespeare WilliamSee RemarksOct 12, 2021 Buy$16.0062510,000388,949Oct 14, 2021, 05:00 PM
Rock Springs Capital Management LP10% OwnerOct 12, 2021 Buy$16.00250,0004,000,000599,320Oct 14, 2021, 05:00 PM
ORBIMED ADVISORS LLCDirectorOct 12, 2021 Buy$16.0062,5001,000,000499,150Oct 14, 2021, 05:00 PM
ORBIMED ADVISORS LLCDirectorOct 12, 2021 Buy$16.00562,5009,000,00016,339,518Oct 14, 2021, 05:00 PM
Omega Fund VI, L.P.Former 10% ownerOct 12, 2021 Buy$16.00187,5003,000,000711,479Oct 14, 2021, 04:40 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Shakespeare WilliamSee Remarks11/06/202380,347
GORDON CARL LDirector07/17/20231,463,793
ORBIMED ADVISORS LLCDirector07/17/20231,463,793
Foresite Capital Management V, LLC10% Owner07/17/20232,079,000
Foresite Capital Management V, LLC10% Owner12/29/20222,500,000
HAYDEN DONALD J JRDirector12/29/2022500
HAYDEN DONALD J JRDirector12/30/202249,489
Dahms Bradford D.Chief Financial Officer11/30/20229,999
CLACKSON TIMOTHY PPresident and CEO11/11/202216,995
GORDON CARL LDirector11/07/20221,000,320
ORBIMED ADVISORS LLCDirector11/07/20221,000,320
GORDON CARL LDirector01/20/2022348,250
GORDON CARL LDirector01/19/2022114,864
GORDON CARL LDirector01/21/20221,115,603
ORBIMED ADVISORS LLCDirector01/21/20221,115,603
ORBIMED ADVISORS LLCDirector01/20/2022348,250
ORBIMED ADVISORS LLCDirector01/19/2022114,864
GORDON CARL LDirector01/11/202289,319
GORDON CARL LDirector01/13/2022163,328
GORDON CARL LDirector01/12/2022190,104
ORBIMED ADVISORS LLCDirector01/13/2022163,328
ORBIMED ADVISORS LLCDirector01/12/2022190,104
ORBIMED ADVISORS LLCDirector01/11/202289,319
CLACKSON TIMOTHY PPresident and CEO12/21/202125,381
Dahms Bradford D.Chief Financial Officer12/21/202120,000
GORDON CARL LDirector10/12/20211,000,000
GORDON CARL LDirector10/12/20219,000,000
Shakespeare WilliamSee Remarks10/12/202110,000
Rock Springs Capital Management LP10% Owner10/12/20214,000,000
ORBIMED ADVISORS LLCDirector10/12/20211,000,000
ORBIMED ADVISORS LLCDirector10/12/20219,000,000
Omega Fund VI, L.P.Former 10% owner10/12/20213,000,000
Load More Insider Transactions
FUNDS WITH A POSITION IN THESEUS PHARMACEUTICALS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ORBIMED ADVISORS LLC17,713,6001.43%No changeOther
BLACKROCK INC.1,425,2340.00015%6.32%Other
GEODE CAPITAL MANAGEMENT, LLC407,8220.00017%0.55%Other
RENAISSANCE TECHNOLOGIES LLC271,6000.0017%115.22%Other
DRIEHAUS CAPITAL MANAGEMENT LLC232,6930.00814%ExitedGrowth
UBS OCONNOR LLC12,5170.00365%-93.1%Value
CHANGE IN SHARES OUTSTANDING FOR THESEUS PHARMACEUTICALS INC
STOCK BUYBACKS FOR THESEUS PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
0.15%
1Q
09/30/2023
03/31/2023
3.38%
2Q
09/30/2023
12/31/2022
13.17%
3Q
09/30/2023
09/30/2022
13.52%
4Q
09/30/2023
06/30/2022
14.02%
5Q
09/30/2023
03/31/2022
14.52%
6Q
Load More

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
0.15%
1Q
03/31/2023
3.38%
2Q
12/31/2022
13.17%
3Q
09/30/2022
13.52%
4Q
06/30/2022
14.02%
5Q
03/31/2022
14.52%
6Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR THESEUS PHARMACEUTICALS INC
LOADING...